Business Wire

MODULEX

5.5.2022 15:02:06 CEST | Business Wire | Pressemeddelelse

Del
Modulex A/S med hovedkontor i Billund afsluttede 2021 med et økonomisk godt resultat på trods af endnu et udfordrende pandemiår.

Modulex A/S er globalt markedsledende inden for visuel kommunikation med 30 salgsenheder og flere produktionsfaciliteter rundt omkring i verden. Modulex A/S leverer wayfinding og arkitektoniske skilteløsninger samt multi-site brandimplementering og er den førende producent af systemskilte på verdensplan.

Koncernen sluttede 2021 med et EBITDA resultat på 17 mio. kr.

Mens koncernen som helhed leverede et flot resultat, er flere salgsenheder som fx Modulex Hospitality, der primært leverer skilteløsninger til internationale hotelkæder og ferieresorts, fortsat alvorligt påvirket af den globale pandemi og er først begyndt at se tegn på opsving i år. På trods af at det mange steder stadig er vanskeligt fysisk at besøge projekter og kunder, holdt de lokale kontorer verden over fast. Globalt set har Modulex Gruppen haft det bedste år i koncernens historie og har i løbet af året leveret og implementeret nogle meget store virksomhedsrebrands i både USA og Vesteuropa.

”Set i lyset af det pres, vi oplever på leveringstider og råmaterialer som aluminium, er vores resultat meget flot," siger Ketil M. Staalesen, administrerende direktør og hovedaktionær i Modulex Gruppen. "Vores produktionsteam udnyttede partnerskaber etableret gennem mange års samarbejde til at sikre, at vi kunne imødekomme vores kunders krav. Vores forretningsudviklingsstrategi fokuserede på at fremme miljøvenlige produkter som Etronit og Greenbond™, som er mindre påvirket af leveringsmæssige udfordringer."

Modulex Gruppen vil i 2022 fokusere på design-build-strategien, globale kunder, mere miljøvenlige produkter og lanceringen af ​​den cloud-baserede projektstyringssoftware e-Modulex. Modulex har allerede indgået nye.

"2022 bliver stadig en udfordring," siger Staalesen. “Men vores solide forretningsstrategi og vores ledelsesteams evne til at kæmpe gennem de seneste to år inspirerer mig. Jeg kunne ikke være mere stolt af dem, og jeg forventer, at vi overgår vores forventninger i år."

www.modulex.com

Om Modulex Gruppen:

Modulex Gruppen, som blev grundlagt i 1963 af LEGO-koncernen og som siden 2009 har været ejet af ledelsen samt andre eksterne investorer, er global markedsleder inden for visuel kommunikation og brandimplementering. Med rod i dansk designekscellence og et modulært skiltekoncept har Modulex udviklet sin platform yderligere med design, wayfinding, brugerdefinerede løsninger og brandimplementeringer. Fabrikken i Billund, som er ISO 9001-certificeret, lancerede i 2019 en mere miljøvenlig produktlinje. Modulex Billund blev tildelt Green Network-diplomet for niende år i træk. Modulex Gruppen har fem fabrikker globalt. Koncernen er repræsenteret i over 300 byer på tværs af 45 lande, hvilket giver Modulex Gruppen den nødvendige rækkevidde og evne til at leve op til sit løfte om global vision, lokal rækkevidde og én virksomhed.

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye